Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
PaperCitations, authors & open-access status
4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 45 citations, 2025 year and bronze oa status.
45
Citations
2025
Year
bronze
OA Status